Table 1. Comparison of our rotenone ST models with other models.

	Rot ST	MPTP ST[48]	Rot SYS[15], [20], [49]	MPTP SYS[47], [50], [51], [52], [53]
Animal	Rat	Rat	Rat	Mouse
Instrument	ST	ST minipump	S.C or Osmotic minipump	S.C or Osmotic minipump
Inclusion formation	Yes	Only in striatum not SNc	Yes	Only in continuous low-level exposure models[47]
Nutritional status	Good	Good	Supplementation by gavage	Data not shown
Peripheral toxicity	No	No	Yes	Theoretically, but data not shown
Pathogenetic research	Yes	Yes	Yes	Yes
Pathophysiological research	Yes	Yes	Yes	Yes
Drug screening	Yes	Yes	Limit	Limit
Variability	Low	Low-medium	Medium	Low-medium
Mortality	Low	Low	Medium	Low-medium
Slow progression	Yes	Yes	Yes, with serious consequence	In some models
Selective degeneration	Yes	Yes	No	Yes
Long-term progression	Yes	data not shown	No	In continuous low-level exposure models
Extensive involvment	Yes	No	Yes, with serious consequence	Yes
Cost	Low	medium-high	Medium-high	Medium-high

Data on the rotenone ST and SYS administration models are from our study and other studies, while data on the MPTP models are all from reports by others. Animal, animal used for the research; Instrument, special instrument or routes of administration; Nutritional status, the nutritional status of PD animal models and whether supplementation is required; Peripheral toxicity, peripheral organ toxicity caused by the neurotoxin; Application, whether the model is suitable for the study of pathogenesis, pathophysiological research, or drug screening of PD; Slow progression, idiopathic PD-like slow progression; Selective degeneration, selective degeneration of DA neurons; Long-term progression, long-term (more than three months) progression without intervention; Extensive involvement, ability to reproduce extensive pathological involvement observed in PD patients; Cost, costs of neurotoxin drugs, instruments, nutritional supplementation (ST, Stereotaxical Infusion; SYS, Systemic administration; S.C., subcutaneous injection).